STATE STREET CORP Initiates New Position in Gilead Sciences, Inc. (GILD)

STATE STREET CORP, a registered investment adviser, initiated a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during Q4 2025, according to its most recent 13F filing with the Securities and Exchange Commission.

The institutional investor purchased 60,240,518 shares of the Healthcare company, valued at approximately $7.4B as of the filing date.

Gilead Sciences, Inc.'s stock currently trades at $152.91 with a market capitalization of $152.9B.